NFE2L2 and cancer: This last finding was confirmed by a different group which reported a prevalence of KEAP1-NFE2L2 (31%) alterations in tumors with high neuroendocrine gene expression, mainly co-occurring with STK11 and KRAS genes to exert a synergic role of tumorigenesis enhancement and cancer progression [60].